Clay B Siegall bought $250K of Shattuck Labs (STTK)
Executed Jun 9, disclosed Jun 11, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 11), the stock returned +55.7% (delay-adjusted); from the execution session (Jun 9), +72.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Clay B Siegall (President and CEO) filed 5 Form 4 reports in the trailing twelve months (5 purchases, 0 sales), most often in Immunome, Inc. (IMNM). Across 5 priced purchase filings, the average 21-session return was +28.7% from execution and +24.2% from disclosure (delay-adjusted; derived). The largest single filing was $1000K of IMNM (46,511 sh × $21.50, as filed), executed Dec 18 2025.
Healthcare · Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→